Intel Corporation rose 4.36% on Thursday as Nvidia's forecast revived confidence in AI infrastructure spending.
Nvidia's forecast lifted Intel 4.36%; the close remains below Intel's recent $95 share-sale price.
| Company | Close | Move | Volume | Trailing P/E |
|---|---|---|---|---|
| Intel | $92.09 | +4.36% | 100.56M | N/M |
| Nvidia | $227.98 | +8.72% | 298.91M | 28.6× |
| AMD | $476.67 | −0.86% | 16.44M | 122.5× |
| Micron | $935.39 | −0.36% | 28.84M | 21.2× |
The split tape matters: Thursday rewarded Intel's AI exposure, but the whole semiconductor group did not rally.
| Q2 revenue | $16.1B | +25% |
| GAAP gross margin | 40.4% | +12.9 pts |
| GAAP operating margin | 11.1% | +35.8 pts |
| Non-GAAP net income | $2.2B | vs. loss |
| GAAP net result | −$11.0B | loss |
Revenue and margins rose sharply, but the GAAP loss kept earnings quality in focus.
Intel sold 210.5 million shares at $95, creating a clear dilution and execution benchmark.
Nvidia's forecast lifted Intel, yet no new Intel design win was announced.
Intel's 4.36% gain says the market sees value in its exposure to expanding AI budgets. The harder test is conversion: foundry utilization, server share, margin durability and cash generation must justify both a $470 billion valuation and the new capital raised at $95.
Record net new ARR and stronger cash conversion pushed the stock near fresh highs. The valuation now leaves less room for a routine quarter.
Market close: Aug. 27, 2026, 16:00 EDT · Financials: quarter ended July 31, 2026The pre-report reference is inferred from the 20.5% one-day move. Closing data are timestamped Aug. 27, 2026, 16:00 EDT.
Net new ARR accelerated faster than total ARR. Falcon Flex ARR exceeded $2.29B and grew 101%, showing larger platform commitments rather than a narrow seat expansion.
| Revenue guide midpoint | $6.001B |
| Prior midpoint | $5.935B |
| Guide increase | $66M |
| Q3 revenue midpoint | $1.526B |
| Metric | Q2 FY27 | Change |
|---|---|---|
| Revenue | $1.471B | +26% |
| Subscription revenue | $1.400B | +27% |
| GAAP subscription margin | 78% | +1 pt |
| Operating cash flow | $530.3M | +59% |
| Free cash flow | $377.4M | +33% |
| GAAP operating loss | ($33.2M) | improved $72.3M |
Adoption rates among subscription customers as of July 31, 2026.
| Company | Ticker | Daily move |
|---|---|---|
| Okta | OKTA | +28.6% |
| CrowdStrike | CRWD | +20.5% |
| Palo Alto Networks | PANW | +12.8% |
| ServiceNow | NOW | +10.0% |
Software and security stocks also benefited from renewed AI spending confidence.
| Implied equity value | ~$238B |
| FY27 guide midpoint multiple | ~39.7× sales |
| Raised analyst targets | $238–$250 |
| Upside to target range | 4.4%–9.7% |
| Consensus | Buy · 44 analysts |
Equity value uses $227.96 and 1.044B diluted weighted-average shares. It is an approximation, not the exchange-reported market capitalization.
Valuation risk is immediate: raised price targets sit close to the market price.
Other watchpoints: long enterprise sales cycles, intense platform competition, acquisition integration, and $399.0M of quarterly stock-based compensation.
Settlement snapshot for August 27, 2026. Updated at 21:06 EDT / August 28, 03:06 CEST.
Brent settled 5.5% above EIA's third-quarter average and 15.0% above its fourth-quarter forecast.
| Commercial crude stocks | 428.9M bbl 1% above five-year average |
| Weekly crude change | +0.1M bbl |
| Gasoline stocks | −2.5M bbl 6% below five-year average |
| Refinery utilization | 97.4% |
| Refinery inputs | 17.4M b/d |
| Channel | Signal |
|---|---|
| Inflation | Upward Higher crude lifts refined-product and freight costs. |
| Airlines & transport | Margin risk Fuel hedges determine near-term sensitivity. |
| Producers | Cash-flow support WTI above $80 strengthens upstream economics. |
| Refiners | Mixed Feedstock rises while gasoline stocks remain tight. |
| Scenario | Price pressure | Evidence to watch |
|---|---|---|
| Verified Hormuz corridor | Downward | Higher tanker counts, lower freight and insurance rates. |
| Diplomacy remains stalled | Premium persists | Brent–WTI spread holds above $6. |
| Further military escalation | Sharp upside risk | Supply outages, shipping delays and wider refined-product cracks. |
| Demand disappoints | Offsets risk premium | Inventory builds and weaker refinery runs. |
Cost controls and a 15% workforce reduction lifted the earnings outlook. Revenue grew just 0.8%, leaving shares almost unchanged after hours.
Q2 FY2027Reported Aug. 27, 2026The margin expansion is the dominant signal. Customer and recurring-revenue growth remain modest.
| Metric | New | Prior | Midpoint change |
|---|---|---|---|
| FY revenue | $491.5M–$496.5M | $488.5M–$496.5M | +0.3% |
| FY adj. EPS | $1.33–$1.37 | $1.27–$1.32 | +4.2% |
| Q3 revenue | $123M–$125M | — | New |
| Q3 adj. margin | 26.5%–27.5% | — | New |
Bull case: The restructuring protects cash generation and supports a higher EPS range. Q2 beat revenue guidance, and free cash flow improved.
Bear case: ARR grew only 0.4% and retention stayed below 100%. The stock already trades above the average analyst target.
Watch next: Q3 revenue of $123M–$125M, adjusted margin of 26.5%–27.5%, retention and the pace of restructuring charges.
Revenue beat consensus by roughly $76 million and EPS beat by $0.36, yet the stock reversed lower. The raised annual EPS midpoint increased less than 1%, while gross margin slipped 10 basis points.
| Metric | Q2 FY25 | Q2 FY26 | YoY |
|---|---|---|---|
| Net sales | $2.788B | $3.036B | +8.9% |
| Comparable sales | 6.7% | 3.8% | −290 bp |
| Gross margin | 39.2% | 39.1% | −10 bp |
| Operating income | $344.9M | $379.6M | +10.1% |
| Diluted EPS | $5.78 | $6.55 | +13.3% |
| Metric | Prior | Updated |
|---|---|---|
| Sales growth | 6.0%–7.0% | 6.7%–7.2% |
| Comparable sales | 2.5%–3.5% | 3.2%–3.7% |
| Operating-income growth | 6.5%–9.0% | 8.3%–9.3% |
| Diluted EPS | $28.36–$28.80 | $28.70–$29.00 |
Watch: Space NK mix, comparable-sales deceleration, gross margin, inventory, consumer confidence and cash funding for repurchases.
The fundamentals beat estimates, but not elevated AI expectations. Q3 revenue guidance exceeded consensus by about 4%, while the non-GAAP gross-margin midpoint falls 90 basis points sequentially.
| Metric | Q2 FY26 | Q2 FY27 | YoY |
|---|---|---|---|
| Revenue | $2.006B | $2.739B | +36.5% |
| GAAP operating income | $290.1M | $459.7M | +58.5% |
| GAAP gross margin | 50.4% | 53.1% | +270 bp |
| Operating cash flow | — | $605.5M | — |
| Metric | Guide midpoint | Consensus | Premium |
|---|---|---|---|
| Revenue | $3.15B | $3.03B | +4.0% |
| Adjusted EPS | $1.10 | $1.07 | +2.8% |
| Non-GAAP gross margin | 58.0% | — | −90 bp QoQ |
Revenue midpoint implies roughly 15% sequential growth.
Watch: custom-silicon ramps, optical demand, customer concentration, supply, gross-margin conversion and cash returns.
| Operating ARR | $1.0B |
| Contracted 2026 ARR | $4.0B |
| 2026 IT capacity | ~0.3GW |
| 2027 IT capacity target | ~0.8GW |
| Recent revenue / MW | >$20M |
| Customer prepayments | 45–55% GPU capex |
| Metric | FY25 | FY26 | Change |
|---|---|---|---|
| Total revenue | $501.0M | $707.0M | +41.1% |
| AI Cloud revenue | $16.4M | $128.8M | +685% |
| Adjusted EBITDA | $269.7M | $245.7M | -8.9% |
| Net income/(loss) | $86.9M | -$702.6M | NM |
| Regular close | $40.53 |
| After-hours | $38.11 |
| Implied value change | ~-$865M |
| 52-week range | $22.63–$76.87 |
| Ratings | 7 Buy / 2 Hold / 1 Sell |
| Average target | $77.44 |
Watch: quarterly adjusted EBITDA fell 67.7% sequentially as staffing and platform costs arrived before the revenue ramp. Deferred revenue drove $1.722 billion of quarterly operating cash flow.
Market snapshot: August 27, 2026, 17:30 EDT · Quarter ended July 31
Bar lengths are normalized within each comparison, not a common scale.
| Metric | Current | Investor signal |
|---|---|---|
| Q3 subscription revenue | ~$2.515B | Broadly in line |
| FY subscription revenue | $9.94–$9.95B | Tiny midpoint raise |
| New buyback authorization | $4.0B | ~9% of AH value |
| After-hours value loss | ~$3.3B | 7.02% move |
| Consensus | Outperform |
| Analysts | 41 |
| Average target | $188.21 |
| Median target | $202.00 |
| Target range | $92–$275 |
| Upside to average | 4.6% |
Watch enterprise IT budgets, large-deal timing, AI pricing, Financials adoption and acquisition speculation. Extended-hours liquidity can amplify the move.
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | $427.3M | $309.9M | +38% |
| Subscription ARR margin | 14.0% | 9.4% | +4.6 pp |
| Non-GAAP gross margin | 81.0% | 81.6% | −0.6 pp |
| Free cash flow | $65.7M | $57.5M | +14% |
| FCF margin | 15% | 19% | −4 pp |
| Metric | Prior range | New range | Midpoint lift |
|---|---|---|---|
| Revenue | $1.638B–$1.648B | $1.685B–$1.693B | +$46M |
| Subscription ARR | $1.854B–$1.862B | $1.880B–$1.885B | +$24.5M |
| Free cash flow | $293M–$303M | $323M–$333M | +$30M |
| Adjusted EPS | $0.25–$0.35 | $0.47–$0.53 | +$0.20 |
3,084 large customers+23% YoY$1.75B liquidity
Extended-hours liquidity can distort price discovery. Rubrik remains GAAP-loss-making. Non-GAAP gross margin slipped 0.6 point, free-cash-flow margin fell four points, and a record-high setup leaves little room for execution misses.
Sources: Rubrik/Business Wire results, Rubrik prior guidance, Public after-hours data, WSJ market data and Yahoo Finance analyst data. Figures are company-reported unless otherwise stated.
Midpoints: revenue $1.200B → $1.2045B; operating income $120M → $126M; EPS $0.35 → $0.31; share count 350M → 361M.
38 ratings aggregated by Robinhood. Ratings are not investment advice.
| Registry field | Before | Aug. 26 update |
|---|---|---|
| Site footprint | Original site set | Baylor College of Medicine added |
| Recruitment | Not yet recruiting | Unchanged |
| Enrollment | 20 | Unchanged |
| Estimated start | Jul. 31, 2026 | Aug. 31, 2026 |
| Primary/final completion | Mar. 31, 2027 | Aug. 31, 2027 |
| Path | Confirmation signal | What would challenge it |
|---|---|---|
| Bull | Recruitment begins; FDA pathway gains clarity; short covering persists | Further trial slippage or weak dosing demand |
| Base | Registry edit stays procedural; shares consolidate into the next data event | Company-specific disclosure changes the evidence set |
| Bear | Delay and safety concerns dominate; squeeze fades | Fast activation plus credible label-expansion progress |
| Metric | Latest | Signal |
|---|---|---|
| Q1 FY2027 bookings | $1.39B | −3% year on year; slightly above guidance |
| Recurrent consumer spending | 84% of bookings | −1% year on year |
| FY2026 bookings | $6.72B | Baseline before GTA VI launch year |
| GTA V installed base | >230M units | Proof of franchise durability |
| GTA VI pre-orders | “Unprecedented” | Management description; not yet recognized sales |
Search attention and the showcase are strong. The stock still fell 2.12%, suggesting investors want execution evidence, not another anticipation cycle.
At $228.50, the market discounts roughly 30% upside to the analyst target. That spread also embeds delay, launch-quality and mobile-performance risk.
The collection directly enters Xbox hardware revenue at a 12.5% premium to the standard 1TB Series X. A sellout would support pricing power and average selling price, but even an aggressive 250,000-unit scenario produces about $225 million of gross sales—only 1.7% of one recent More Personal Computing quarter.
Watch: production volume, sell-through speed, channel inventory, discounting before November 13 and any hardware-margin disclosure. Scarcity can create a sellout without proving mass-market demand. The 1.5% MSFT gain occurred during a broad technology rally and should not be attributed to Xbox alone.
| Facility | 147,215 sq. ft. |
| Grade C / ISO 7 suites | 9 |
| Grade D / ISO 8 suites | 6 |
| Products in scope | MuseCells, exosomes, secretome |
| Potential jobs | >200, non-binding |
| Measure | Latest disclosed |
|---|---|
| 2025 revenue | $26.6M |
| 2025 net loss | -$91.7M |
| Year-end cash | $6.2M |
| Accumulated deficit | $991.5M |
| Potential annualized purchases | >$60M |
| Ticker | Price | Day | Market value |
|---|---|---|---|
| CELU | $1.94 | +120.4% | $51.4M |
| LGVN | $6.73 | -4.3% | $211.2M |
| DYAI | $0.65 | -1.2% | $23.8M |
| MRKR | $1.48 | +2.1% | $28.0M |
| Stage | Evidence investors need | Risk |
|---|---|---|
| Initial project | Technology transfer and qualified process | Yield, comparability and release criteria |
| Expansion | Binding purchase orders and production volumes | $300M estimate may not convert |
| Cash flow | Revenue collection and margin disclosure | Financing and dilution |
| Listing | Compliance plan due Sept. 4 | Two overdue Form 10-Q filings |
The common stock added roughly $5.2 billion of quoted value. The bitcoin reserve gained about $1.9 billion at the same snapshot.
Before debt, preferred equity, tax and other claims.
| Measure | Reading | Why it matters |
|---|---|---|
| BTC acquisition cost | $63.36B / $75,385 each | Current token price sits 6.6% higher |
| USD Reserve | $5.10B | Supports dividends and interest |
| USD Cash | $1.59B | Flexible treasury deployment |
| Q2 long-term debt | $6.7B | Down 18% in the quarter |
| Q2 preferred equity | $14.4B | Senior claim to common stock |
| Q2 software revenue | $122.4M | Up 6.9% year over year |
| Action, Aug. 17–23 | Amount | Investor interpretation |
|---|---|---|
| MSTR shares sold | 18.26M | Common-stock dilution |
| Net proceeds | $2.0065B | About $109.88 per share |
| STRC repurchase | $136.4M | Reduces preferred claim |
| USD Reserve increase | $300M | Extends obligation coverage |
| Bitcoin traded | None | 840,447 BTC unchanged |
MSTR’s daily gain materially exceeded bitcoin’s. That leverage can reverse. Common issuance, preferred dividends, debt service, tax changes, regulation and contraction of the equity multiple can outweigh a stable token price.
Primary data: Strategy Aug. 24 Form 8-K and Q2 2026 results. Market data timestamped above.
Salesforce market data at 10:28 EDT; operating metrics released Aug. 26.
| Company | Price | Move |
|---|---|---|
| ServiceNow (NOW) | $137.16 | +9.03% |
| Salesforce (CRM) | $248.29 | +20.75% |
| Workday (WDAY) | $197.39 | +3.48% |
| Oracle (ORCL) | $150.84 | +1.32% |
NOW at 10:37 EDT; peer prices at about 10:28 EDT on Aug. 27, 2026.
2:40 p.m. EDT today
ServiceNow CFO Gina Mastantuono speaks at Deutsche Bank's technology conference.
Next quarter
Watch whether cRPO holds near 20% constant-currency growth and AI ACV converts into subscriptions.
Risk
The rally is a peer read-through. Average target upside is now only 3.7%.
The U.S. search phrase “now stock” also points to ServiceNow's expanded Tech Mahindra partnership. It was announced Aug. 20, not today. Tech Mahindra says its ServiceNow deployment handles more than 100,000 monthly cases across 90 countries, supports 150,000 employees and has optimized about 25% of first-level support work.
The AI-memory read-through remains strong. Price action says investors still want Micron-specific proof on HBM volume, pricing and margins.
August 27 value is intraday at 09:39 EDT; earlier values are official closes. The stock opened at $967.01 before fading.
| Metric | Current / latest | Comparison | Investor reading |
|---|---|---|---|
| Fiscal Q3 revenue | $41.46B | $23.86B prior quarter | +73.8% sequential |
| Operating cash flow | $25.39B | $11.90B prior quarter | Cash conversion strengthened |
| Adjusted free cash flow | $18.3B | $7.1B capex | Funds expansion internally |
| Adjusted gross margin | 84.9% | 74.9% prior quarter | Exceptional, hard to sustain |
| Forward P/E | 6.5× | 21.2× trailing | Large earnings-cycle assumption |
| Net cash | $23.75B | $21.03 per share | Balance-sheet cushion |
HBM is stacked memory placed beside AI accelerators. Higher accelerator shipments increase the addressable memory content, but Micron’s realized revenue still depends on qualification, allocation, pricing and yield.
| Reference | Target / value | Upside from $943.46 | Implied FY2027 P/E |
|---|---|---|---|
| Current price | $943.46 | — | 6.1× |
| BMO / Mizuho | $1,300 | 37.8% | 8.4× |
| Analyst average | $1,515 | 60.6% | 9.8× |
| Analyst low | $361 | −61.7% | 2.3× |
| Analyst high | $2,200 | +133.2% | 14.2× |
| Measure | Period | Value |
|---|---|---|
| Close before catalyst | Aug. 26 | $0.34 |
| Premarket range | Aug. 27, 07:30 EDT | $0.66–$0.68 |
| Q2 revenue | Quarter ended June 30 | ~$0.4M |
| H1 revenue | Six months ended June 30 | $1.4M · +112% |
| Q2 operating loss | Quarter ended June 30 | $4.2M · −34% |
| Q2 operating cash use | Quarter ended June 30 | $5.2M · −18% |
| Cash | June 30 | $2.79M |
The market added almost one quarter's cash consumption. That is meaningful for a microcap, but small beside the funding needed to commercialize diagnostics.
Status at Aug. 27: validation completed; commercial discussions disclosed, but no contract value or revenue timetable announced. The $2.8B annual sepsis opportunity is a company estimate, not guidance.
Flagship SUV return meets a low-margin growth plan.
Market data: August 26, 2026, 15:30 JST · Dashboard: August 27, 2026, 03:42 JST
Equity-value change uses the ¥9.20 share gain and 1.34 billion shares outstanding.
| Signal | Verified measure |
|---|---|
| Global return | After 5 years |
| Lifetime sales | >3.25M units |
| Historical markets | >170 |
| Dakar record | 12 wins |
| Platform | Triton ladder frame |
| Drive control | S-AWC |
Lifetime Pajero sales equal 3.8 times Mitsubishi's current full-year volume target.
Reveal date and triple multi meter confirmed.
Pricing, powertrain and initial markets are key.
Management links Pajero to sales growth.
857,000 retail units and 2.8% margin.
Sources: Mitsubishi Motors official Pajero site and releases; Mitsubishi Motors Q1 presentation summary; StockAnalysis and Investing.com market and consensus data. Currency is Japanese yen. Estimates are explicitly marked.
| Metric | Q2 2026 | YoY |
|---|---|---|
| Total sales | $5.442B | +7.5% |
| Cardiovascular | $3.624B | +8.3% |
| MedSurg | $1.818B | +5.9% |
| Adjusted EPS | $0.86 | +14.7% |
| GAAP net income | $907M | +13.8% |
| Signal | Current reading |
|---|---|
| FY26 sales growth | 5.5%–6.5% reported |
| FY26 adjusted EPS | $3.28–$3.32 |
| Q3 adjusted EPS | $0.80–$0.82 |
| P/E | 19.38× |
| Analyst consensus | Buy · 31 analysts |
| Average target | $62.69 · 31% upside |
| Recovery path | Revenue effect | Investor implication |
|---|---|---|
| Faster than Stryker | Below $316M | More orders may shift within the quarter rather than disappear. |
| About three weeks | $316M–$369M | Evercore's 600–700 bp scenario; a guide cut becomes plausible. |
| Longer or broader | Above $369M | Margin pressure and customer disruption could outlast shipment delays. |
Boston Scientific has not determined whether the incident is reasonably likely to be material. The full scope, recovery duration and any data loss remain unknown.
Sources: Boston Scientific Q2 2026 results; Reuters, Aug. 26, 2026; Google Finance quote at 09:40:21 EDT; StockAnalysis analyst consensus. The $316M–$369M range is a scenario calculation, not company guidance.
